Skip to main content

Table 2 Time-varying covariates. Means ± SD at baseline and change after 2-years follow-up in untreated and treated MS groups

From: Influence of Interferon beta treatment on quality of life in multiple sclerosis patients

  Untreated n. 77 IFN-β treated n.41 p-value*
Time-varying covariates Baseline Change Baseline Change Baseline Change
Relapse rate** 0.2 ± 0.3 0.0 ± 0.4 0.7 ± 0.5 -0.1 ± 0.6 <0.0001 0.37
EDSS 3.1 ± 1.7 0.4 ± 0.8 3.0 ± 1.8 0.4 ± 1.1 0.84 0.93
BDI 9.5 ± 7.7 1.3 ± 10.3 10.8 ± 9.2 2.2 ± 9.8 0.57 0.88
FSS 2.5 ± 1.8 1.1 ± 1.7 2.8 ± 1.9 1.2 ± 1.8 0.53 0.75
MMSE-c 28.5 ± 2.0 -0.6 ± 2.4 28.1 ± 3.7 -0.5 ± 2.5 0.78 0.70
MSQoL-54 Measures       
Physical health composite score 65.5 ± 21.4 -5.5 ± 17.2 65.1 ± 22.3 -9.1 ± 18.9 0.91 0.45
Mental health composite score 69.1 ± 19.8 1.2 ± 20.2 71.6 ± 18.2 -12.1 ± 19.1 0.54 0.006
Physical function 67.7 ± 35.8 -2.3 ± 14.7 69.5 ± 35.4 -8.8 ± 19.1 0.80 0.13
Health perceptions 47.5 ± 23.4 -3.0 ± 23.1 48.7 ± 22.7 -6.0 ± 26.9 0.76 0.64
Energy 47.7 ± 22.6 1.1 ± 23.0 47.0 ± 23.0 -1.2 ± 23.0 0.91 0.57
Role limitation-physical 67.6 ± 43.5 -4.6 ± 42.9 65.2 ± 40.7 -14.3 ± 41.8 0.48 0.52
Bodily pain 79.7 ± 25.7 -8.7 ± 30.9 74.0 ± 29.7 -8.1 ± 28.6 0.39 0.41
Sexual function 83.1 ± 26.6 -6.0 ± 35.6 81.5 ± 27.0 -12.0 ± 36.5 0.67 0.62
Social function 74.2 ± 23.3 -5.8 ± 23.4 74.4 ± 21.3 -10.0 ± 21.5 0.87 0.49
Health distress 70.8 ± 23.0 -2.0 ± 31.6 71.9 ± 20.4 -13.3 ± 24.0 0.98 0.06
Overall quality of life 67.5 ± 19.0 -1.0 ± 22.3 64.4 ± 18.8 -8.6 ± 24.3 0.46 0.17
Cognitive function 78.6 ± 20.6 -0.4 ± 23.0 82.4 ± 20.6 -12.2 ± 23.9 0.31 0.06
Emotional well-being 57.1 ± 22.8 5.4 ± 43.2 59.5 ± 16.7 -21.6 ± 42.5 0.65 0.014
Role limitation- emotional 70.6 ± 43.3 0.4 ± 27.2 78.9 ± 36.3 -6.4 ± 21.0 0.37 0.22
Satisfation with sexual function 60.4 ± 26.7 2.0 ± 34.9 54.3 ± 30.6 -3.7 ± 37.0 0.33 0.40
Change in health 47.1 ± 19.9 0.5 ± 21.3 50.6 ± 22.7 4.6 ± 35.5 0.43 0.36
  1. *p-values refer to t-test between treated and untreated groups at baseline and after 2 years follow-up.
  2. **Relapse rate was evaluated in the 2-years preceding study entry (baseline)and after 2 years of follow-up (change)